Top in rheumatology: Diagnosing MIS-C vs. COVID-19 pneumonia, anakinra for pain relief
Pre-existing conditions can help distinguish between multisystem inflammatory syndrome and COVID-19 pneumonia in pediatric patients, according to experts.
A recent analysis comparing the clinical manifestations of both conditions was the top story in rheumatology last week.
Another top story was about a study investigating the efficacy and safety of anakinra. Researchers found that it was comparable to triamcinolone in reducing pain associated with gout flares.
Read these and more top stories in rheumatology below:
Pre-existing conditions, GI symptoms help distinguish MIS-C from COVID-19 pneumonia
While most children with multisystem inflammatory syndrome are previously healthy, those hospitalized with severe COVID-19 pneumonia typically have pre-existing conditions, such as diabetes or obesity, according to data. Read more.
Anakinra comparable to triamcinolone for reducing gout flare pain
Although anakinra is not superior to triamcinolone in affecting gout pain intensity over 24 to 72 hours, it is comparable in pain reduction and even favored in most secondary outcomes, according to data published in Arthritis & Rheumatology. Read more.
Study of COVID-19 provides 'unparalleled' chance to advance autoimmunity knowledge
Studies examining the immunopathogenesis of COVID-19 and its link to immune system dysregulation are providing an “unparalleled opportunity” to learn more about autoimmunity, according to a review published in Pathogens and Immunity. Read more.
Arthritis among most common chronic conditions for US veterans
Arthritis and hypertension are the two most prevalent chronic conditions among U.S. veterans aged 25 years and older, according to data published by CDC researchers in National Health Statistics Report. Read more.
Pegloticase plus immunomodulation boosts responder rates in uncontrolled gout
Combining pegloticase with immunomodulation therapy greatly improves pegloticase response rates in patients with uncontrolled gout, according to a systematic review published in Seminars in Arthritis and Rheumatism. Read more.